← All Nexalin Technology, INC filings

Nexalin Technology, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
NXL
Nexalin Technology, INC
10-K: Nexalin Faces Going Concern, Nasdaq Delisting Amid Losses
Nexalin Technology, Inc. reported significant operating losses and a going concern warning, alongside Nasdaq minimum bid price non-compliance, despite advancing its neurostimulation product pipeline.
NASDAQ
NXL
Nexalin Technology, INC
10-K/A: Nexalin Amends 10-K, Reveals Worsening Losses Amid Growth
Nexalin Technology, Inc. filed an amendment to its annual report, correcting internal control disclosures and refiling financials that show increased revenue but also widening net losses and persistent going concern doubts.
NASDAQ
NXL
Nexalin Technology, INC
10-K/A: Nexalin Technology Files Amendment to 10-K, Includes Insider Trading and Compensation Recoupment Policies
Nexalin Technology files an amendment to its 2024 annual report to include the Insider Trading Policy and Compensation Recoupment Policy exhibits.
NASDAQ
NXL
Nexalin Technology, INC
10-K: Nexalin Technology Reports Fiscal Year 2024 Results, Navigates Regulatory Landscape
Nexalin Technology's 10-K filing reveals ongoing efforts to develop and commercialize neurostimulation products for mental health, while addressing regulatory hurdles and financial challenges.
NASDAQ
NXL
Nexalin Technology, INC
10-K: Nexalin Technology Reports Full Year 2023 Results, Focuses on Next-Gen Device Development and Regulatory Approvals
Nexalin Technology's 2023 annual report highlights a shift towards next-generation device development and regulatory approvals, with a focus on new clinical trials and a virtual clinic model.